Mahadi Baig: New Study Highlights Benefits of Subcutaneous Amivantamab with Lazertinib
Mahadi Baig, Vice President, Head of Solid Tumors, US Medical Affairs at Johnson and Johnson, posted on LinkedIn about recent article by Mariam Alexander et al., published on European Journal of Cancer.
“Excited to share our newest publication demonstrating subcutaneous amivantamab, which simplifies and shortens administration, reduces resource utilization, and enhances treatment experience, is a preferred option for patients receiving amivantamab-lazertinib.”
Title: Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory EGFR-mutated Non-small Cell Lung Cancer: Patient Satisfaction and Resource Utilization Results from the PALOMA-3 Study
Authors: Mariam Alexander, Ying Cheng, Se-Hoon Lee, Antonio Passaro, Alexander I. Spira, Byoung Chul Cho, Sun Min Lim, Yuichiro Ohe, Adnan Nagrial, Jiunn Liang Tan, Vanina Wainsztein, Elisa Ramos, Maria del Rosario Garcia Campelo, Hiroaki Akamatsu, Danny Nguyen, Alexis B. Cortot, Alona Zer, Dilek Erdem, Rachel E. Sanborn, Till-Oliver Emde, Natasha B. Leighl
Read The Full Article at European Journal of Cancer.
More Posts Featuring Mahadi Baig.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023